Shigella Vaccines Market

Shigella Vaccines Market Revenues to Reach US$
Billion/Million by 2026
Shigella is a gram-negative pathogenic enterobacteria that causes severe diarrhea and dysentery
in humans. Symptoms associated with Shigella infection includes fever, stomach pain, tenesmus,
watery diarrhea, vomiting, dehydration, and convulsions. Various strains of Shigella are
encompassed, such as S. dysenteriae, S. flexneri, S. sonnei and S. boydii. Each species of
Shigella has different serotypes classified on the basis of the structure of O-antigens repeats that
are the polysaccharides moiety of the lipopolysaccharide, a virulence factor consist of toxic
lipid. According to the Centers for Disease Control and Prevention (CDC), in 2013, the average
annual incidence of shigellosis in the U.S. was around 5 cases per 100,000 individuals. Bacillary
dysentery with brutal epidemics are caused by S. dysenteriae by the production of shiga toxins
whereas, the endemic form of disease is caused by the S. flexneri and S. sonnei. The bacillary
dysentery is accompanied with fever, rectal inflammation, and abdominal cramps.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1110
According to World Health Organization (WHO), nearly one million people die from Shigella
infection annually. Moreover, the high incidence rate is seen among children less than five
years age, travelers, and military personnel from industrialized economies. Shigella species have
been identified from centuries and it represents a major threat to public health, due to nonavailability of licensed vaccine and thus affecting overall Shigella vaccines market.
Developing vaccine against Shigella infections is difficult, due to the diversity of Shigella species
and their serotypes. Shigella genome is continuously modified by deletion and acquisition of
genes mediated by the mobile genetic elements, such as plasmids, insertion sequences, and
integrons. These modifications are the major foundation for the generation of novel antibiotic
resistant strains and it also leads to the formation of novel Shigella serotype variants. Centers
for Disease Control and Prevention (CDC) in April 2017, warned the physicians and public
health officials in the U.S. by stating that the recent strains of Shigella bacteria shows the
reduced susceptibility to ciprofloxacin, which is one of the main antibiotics recommended by
WHO for the treatment of shigellosis.
Geographically, S. flexneri is the most frequent species occurred worldwide accounting for most
cases in emerging economies. Whereas, the S. sonnei is prevalent in Brazil, China, Vietnam,
and Bangladesh, due to rapid industrialization of these economies. The primary prevention of
Shigella is based on the universal provision of portable sanitation and water methods along
with personal and food hygiene. However, a low cost and effective vaccine would accelerate
disease reduction across the globe.
Joint ventures and collaborations of major players to develop and commercializes the vaccine
are expected to propel the Shigella vaccines market in near future:
Joint ventures and partnership of the players to develop and commercialize Shigella vaccine is
expected to provide momentum to the Shigella vaccines market. For instance, in March 2017,
Hilleman Laboratories, a non-profit organization established with joint venture partnership
between Merck & Co., and Wellcome Trust has entered into an agreement with National
Institute of Cholera and Enteric Disease (NICED) for the development and commercialization of
vaccines against Shigella by 2024. Besides, in June 2016, Immuron- an Australian
biopharmaceutical company entered into an agreement to produce Shigella vaccine with the U.S
Army’s biomedical research lab-Walter Reed Army Institute of Research (WRAIR).
Prokarium and Probiomed in January 2017, collaborated to manufacture orally-administrated
vaccine to prevent diarrhea. The new vaccine is expected to be manufactured as a part of twoyear collaboration having thermostable capabilities for a longer period. The new vaccine is
expected to be delivered to the people living in the remote areas. Thermostable vaccine, which
is manufactured approximately one third of the price of the conventional injectable vaccines
helps to facilities the growth of Shigella vaccines market.
Report includes chapters which deeply display the following deliverable about industry :
• Shigella Vaccines Market Research Objective and Assumption
• Shigella Vaccines Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Shigella Vaccines Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Shigella Vaccines Market, By Regions
• Shigella Vaccines Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Shigella Vaccines Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Shigella Vaccines Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Shigella Vaccines Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
The new research trial drives the Shigella vaccines market:
The University Of Maryland School Of Medicine (UM SOM) in August 2017 received US$ 2.47
Million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop
vaccine against Shigella and Enterotoxigenic Escherichia coli (ETEC) for the treatment of
diarrheal disease. The researchers in the UM SOM’s Center for Vaccine Development (CVD) have
developed Shigella-ETEC prototype vaccine, which has been tested in animals successfully.
Moreover, the latest funding helps to translate prototype to a human vaccine for Phase 1
clinical trials.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/1110
Top Key Players:
The key players present in the global shigella vaccines market include MSD Wellcome Trust
Hilleman Laboratories Pvt. Ltd., Novartis (Novartis Vaccines Institute for Global Health), and
GlaxoSmithKline plc.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Shigella is a gram-negative pathogenic enterobacteria that causes severe diarrhea and dysentery in humans.

Download Report